> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Review Period Set for Jetrea
- URL: https://www.fdaweb.com/review-period-set-for-jetrea/
- Published: 2016-01-04T12:00:00.000Z
- Updated: 2026-09-15T02:24:38.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5134329

*Federal Register* Notice: FDA has determined the regulatory review period for ThromboGenics’ Jetrea (ocriplasmin) is 2,171 days for extending a patent which claims the human biological product. Jetrea is indicated for treating symptomatic vitreomacular adhesion. To view this notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2015-12-23/pdf/2015-32247.pdf?ref=fdaweb.com).